Sanofi takes $250M hit after gamble on J&J E. coli vaccine ends in phase 3 failure Amgen ends Ideaya cancer combination trial after partner unveils rival molecule VC Longwood Fund unveils neuro biotech with $93M, assets licensed from Roche Encoded lays off 29% of staff to fund Dravet syndrome gene therapy trial Galapagos drops one CD19 CAR-T to focus on 'flagship' program Aardvark heads to Nasdaq with $94M IPO to fund more appetite-suppressant trials GSK plans to move vaccine R&D group from Maryland to the Boston area Oligonucleotide stops gene expansion process that drives Huntington's disease: study | 